Search results
...Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell...
WTNH-TV New Haven· 12 hours ago...a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and...
C.J. Sansom, Mystery Novelist Drawn to Tudor England, Dies at 71
New York Times· 3 days agoIt was an assessment of “Tombland,” the seventh work of historical fiction by C.J. Sansom to feature...
Reviva Pharmaceuticals (NASDAQ:RVPH) vs. Bristol-Myers Squibb (NYSE:BMY) Head to Head Survey
ETF DAILY NEWS· 2 weeks agoBristol-Myers Squibb (NYSE:BMY – Get Free Report) and Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) are both medical companies, but which is the better investment? We will compare the ...
Ten years after the Flint water crisis, distrust and anger linger
Michigan Advance via Yahoo News· 12 hours agoProPublica is a Pulitzer Prize-winning investigative newsroom. Sign up for The Big Story newsletter...
Artificial Sweetener Now Classified as ‘Possible Carcinogen'
Mercola· 2 weeks agoThe artificial sweetener aspartame is primarily made up of aspartic acid and phenylalanine. The phenylalanine has been synthetically modified to carry a methyl group, which provides most of ...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 7 days agoAd hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars Agreement clears path for launch of Jubbonti® and Wyost
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 9 hours agoSpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Q1 2024 Earnings Call Transcript May 5, 2024...
Xpovio dosage: Form(s), strength(s), how to use, and more
Medical News Today· 5 days agoGet the facts on Xpovio dosages. You can also learn how to take the drug, which form it comes in,...
Q&A on Reducing COVID-19 Risk for Elderly, Immunocompromised - FactCheck.org
FactCheck.org· 2 weeks agoThe updated COVID-19 vaccines and, in some cases, a new monoclonal antibody can provide increased protection for this group. “At this point, many people have had multiple ...
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society...
Morningstar· 2 weeks ago– Results from Phase 2b ReNeu trial of mirdametinib in NF1-PN accepted for oral presentation – – Additional data from the Phase 3 DeFi trial of OGSIVEO® (nirogacestat) in adults with desmoid tumors also accepted for presentations at ASCO – STAMFORD